ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Liuwei Dihuang Pills Enhance Osteogenic Differentiation in MC3T3-E1 Cells through the Activation of the Wnt/β-Catenin Signaling Pathway

Zhao, Jinlong; Liang, Guihong; Yang, Junzheng; Huang, Hetao; Dou, Yaoxing; Gu, Zhuoxu; Liu, Jun; Zeng, Lingfeng*; Yang, Weiyi*广东省人民医院; 广州中医药大学; 5
Pharmaceuticals2024-1DOI: 10.3390/ph17010099
9阅读
引用收藏
分享

摘要

Objective: The therapeutic efficacy and molecular mechanisms of traditional Chinese medicines (TCMs), such as Liuwei Dihuang pills (LWDH pills), in treating osteoporosis (OP) remain an area of active research and interest in modern medicine. This study investigated the mechanistic underpinnings of LWDH pills in the treatment of OP based on network pharmacology, bioinformatics, and in vitro experiments. Methods: The active ingredients and targets of LWDH pills were retrieved through the TCMSP database. OP-related targets were identified using the CTD, GeneCards, and DisGeNET databases. The STRING platform was employed to construct a protein-protein interaction (PPI) network, and core targets for LWDH pills in treating OP were identified. The GO functional and KEGG pathway enrichment analyses for potential targets were performed using the R package "clusterProfiler". A "drug-target" network diagram was created using Cytoscape 3.7.1 software. The viability of MC3T3-E1 cells was evaluated using the CCK-8 method after treatment with various concentrations (1.25%, 2.5%, 5%, and 10%) of LWDH pill-medicated serum for 24, 48, and 72 h. Following a 48 h treatment of MC3T3-E1 cells with LWDH pill-medicated serum, the protein levels of collagen I, RUNX2, Wnt3, and beta-catenin were quantified using the Western blot analysis, and the activity of alkaline phosphatase (ALP) was measured. Results: A total of 197 putative targets for LWDH pills for OP treatment were pinpointed, from which 20 core targets were singled out, including TP53, JUN, TNF, CTNNB1 (beta-catenin), and GSK3B. The putative targets were predominantly involved in signaling pathways such as the Wnt signaling pathway, the MAPK signaling pathway, and the PI3K-Akt signaling pathway. The intervention with LWDH pill-medicated serum for 24, 48, and 72 h did not result in any notable alterations in the cell viability of MC3T3-E1 cells relative to the control group (all p > 0.05). Significant upregulation in protein levels of collagen I, RUNX2, Wnt3, and beta-catenin in MC3T3-E1 cells was observed in response to the treatment with 2.5%, 5%, and 10% of LWDH pill-medicated serum in comparison to that with the 10% rabbit serum group (all p < 0.05). Furthermore, the intervention with LWDH pill-medicated serum resulted in the formation of red calcified nodules in MC3T3-E1 cells, as indicated by ARS staining. Conclusions: LWDH pills may upregulate the Wnt/beta-catenin signaling pathway to elevate the expression of osteogenic differentiation proteins, including collagen I and RUNX2, and to increase the ALP activity in MC3T3-E1 cells for the treatment of OP.

学科与关键词

关键词
Liuwei Dihuang pillsosteogenicosteoporosisWnt/beta-catenin signaling pathway
相关
加载中…
  • Network Pharmacological Study on Mechanism of the Therapeutic Effect of Modified Duhuo Jisheng Decoction in Osteoporosis
    Huang, Xudong; Zhou, Zhou; Zheng, Yingyi; Fan, Guoshuai; Ni, Baihe; Liu, Meichen; Zhao, Minghua; Zeng, Lingfeng*; Wang, Weiguo*Frontiers in Endocrinology, 2022, 13: 860649.被引 2
  • Analysis of Molecular Mechanism of Erxian Decoction in Treating Osteoporosis Based on Formula Optimization Model
    Yang, Lang; Fan, Liuyi; Wang, Kexin; Chen, Yupeng; Liang, Lan; Qin, Xuemei; Lu, Aiping; Cao, Peng; Yu, Bin*; Guan, Daogang*; Peng, Junxiang*Oxidative Medicine and Cellular Longevity, 2021, 2021: 6641838.被引 27
  • The potential mechanism of Fructus Ligustri Lucidi promoting osteogenetic differentiation of bone marrow mesenchymal stem cells based on network pharmacology, molecular docking and experimental identification
    Kong, Yuanhang; Ma, Xinnan; Zhang, Xin; Wu, Leilei; Chen, Dechun; Su, Bo; Liu, Daqian; Wang, Xintao*Bioengineered, 2022, 13(4): 10640-10653.被引 5
查看全部 →

发表信息

论文状态
公开发表
期刊
Pharmaceuticals
发表日期
2024-01
卷期
第 17 卷, 第 1 期
页码
99
DOI
10.3390/ph17010099
成果收录
SCIE
资助标注
National Natural Science Foundation of China

作者

  • Z

    Zhao, Jinlong (第一作者)

    2 · guangzhou univ chinese med · guangdong prov hosp · guangdong prov acad chinese med sci

  • L

    Liang, Guihong

    2 · guangzhou univ chinese med · guangdong prov hosp · guangdong prov acad chinese med sci

查看全部 9 位作者收起作者
  • Y

    Yang, Junzheng

    5 · guangzhou univ chinese med

  • H

    Huang, Hetao

    2 · guangdong prov hosp · guangzhou univ chinese med

  • D

    Dou, Yaoxing

    2 · guangzhou univ chinese med · guangdong prov hosp · guangdong prov acad chinese med sci

  • G

    Gu, Zhuoxu

    2 · guangzhou univ chinese med

  • L

    Liu, Jun

    5 · guangzhou univ chinese med · guangdong prov acad chinese med sci

  • Z

    Zeng, Lingfeng (通讯)

    2 · guangzhou univ chinese med · guangdong prov hosp · guangdong prov acad chinese med sci

  • Y

    Yang, Weiyi (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417